Charles River Laboratories Intl.’s (CRL) Buy Rating Reiterated at Jefferies Group LLC

Charles River Laboratories Intl. Inc (NYSE:CRL)‘s stock had its “buy” rating restated by research analysts at Jefferies Group LLC in a research note issued to investors on Friday. They presently have a $106.00 price objective on the medical research company’s stock. Jefferies Group LLC’s target price would indicate a potential upside of 19.33% from the company’s current price.

Separately, Evercore ISI raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $86.50 target price for the company in a report on Wednesday, January 4th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $86.15.

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Shares of Charles River Laboratories Intl. (NYSE:CRL) traded down 0.57% during trading on Friday, reaching $88.83. 302,687 shares of the company were exchanged. The firm’s 50 day moving average is $88.56 and its 200 day moving average is $81.11. The firm has a market capitalization of $4.21 billion, a P/E ratio of 27.54 and a beta of 0.99. Charles River Laboratories Intl. has a 1-year low of $67.20 and a 1-year high of $91.57.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Tuesday, February 14th. The medical research company reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.10. Charles River Laboratories Intl. had a return on equity of 25.75% and a net margin of 9.05%. The firm earned $466.80 million during the quarter, compared to the consensus estimate of $441.64 million. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue was up 31.9% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories Intl. will post $5.06 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories Intl.’s (CRL) Buy Rating Reiterated at Jefferies Group LLC” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/04/21/charles-river-laboratories-intl-s-crl-buy-rating-reiterated-at-jefferies-group-llc.html.

In other news, insider David P. Johst sold 13,950 shares of the business’s stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $78.00, for a total value of $1,088,100.00. Following the completion of the sale, the insider now directly owns 174,696 shares in the company, valued at $13,626,288. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Davide Molho sold 11,717 shares of the business’s stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $90.00, for a total value of $1,054,530.00. Following the completion of the sale, the insider now owns 28,266 shares of the company’s stock, valued at $2,543,940. The disclosure for this sale can be found here. Insiders sold 85,932 shares of company stock valued at $7,472,459 over the last three months. 2.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new stake in Charles River Laboratories Intl. during the fourth quarter worth approximately $53,008,000. Marshall Wace LLP boosted its stake in Charles River Laboratories Intl. by 1,058.9% in the fourth quarter. Marshall Wace LLP now owns 469,045 shares of the medical research company’s stock worth $35,737,000 after buying an additional 428,573 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Charles River Laboratories Intl. during the fourth quarter worth approximately $27,886,000. Russell Investments Group Ltd. acquired a new stake in Charles River Laboratories Intl. during the fourth quarter worth approximately $24,845,000. Finally, Alyeska Investment Group L.P. boosted its stake in Charles River Laboratories Intl. by 43.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 846,324 shares of the medical research company’s stock worth $64,481,000 after buying an additional 254,519 shares during the period. Institutional investors and hedge funds own 95.32% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply